Next-Generation In Vitro Diagnostics (IVD) Market Performance Outlook 2026–2030: Revenue to Hit $188.69 Billion at 9.8% CAGR
Uncover key drivers, emerging technologies, and competitive movements shaping the workstation graphics processing unit (gpu) market from 2026–2035 with trusted insights from The Business Research Company
What long-term size projections exist for the Next-Generation In Vitro Diagnostics (IVD) Market covering 2026–2035?
The market size for next-generation in vitro diagnostics (ivd) has experienced rapid expansion in recent years. This market is projected to grow from $117.97 billion in 2025 to $129.89 billion in 2026, achieving a compound annual growth rate (CAGR) of 10.1%. Historically, this growth can be attributed to several factors including the rising prevalence of infectious diseases, the growing burden of chronic conditions, increased adoption of molecular diagnostics, the expansion of clinical laboratory infrastructure, and government funding allocated for diagnostic programs.
The next-generation in vitro diagnostics (ivd) market is projected to experience robust expansion over the coming years. This market is anticipated to reach $188.69 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 9.8%. Key drivers for this growth during the forecast period include a rising demand for precision medicine, the broadening scope of genomic testing applications, an increased uptake of point-of-care diagnostics, advancements in healthcare digitization, and augmented investments in diagnostic research and development. Significant trends observed in the projected period encompass a move towards personalized and companion diagnostics, widespread acceptance of point-of-care and decentralized testing methods, the incorporation of multiplex and high-throughput assays, a heightened need for early disease detection and screening, and the expansion of non-invasive and liquid biopsy diagnostics.
Access Your Free Sample Report for In-Depth Market Insights:
https://www.thebusinessresearchcompany.com/sample.aspx?id=25848&type=smp
Which Drivers Are Impacting The Competitive Landscape Of The Next-Generation In Vitro Diagnostics (IVD) Market?
The expanding need for personalized medicine is projected to drive the growth of the next-generation in vitro diagnostics (IVD) market moving ahead. Precision medicine refers to a healthcare strategy that tailors disease prevention and treatment according to an individual’s genetic profile, environment, and lifestyle. The surge in personalized medicine stems from the increasing availability of genomic data, enabling healthcare providers to formulate targeted treatments based on an individual’s distinct genetic makeup, resulting in enhanced care. Next-generation in vitro diagnostics (IVD) facilitates personalized medicine by offering accurate molecular and genetic insights, thereby allowing for customized treatment and prevention strategies for specific patients. As an illustration, in February 2024, the Personalized Medicine Coalition, a US-based hospital and health care organization, reported that the FDA approved 16 new personalized treatments for rare disease patients in 2023, an increase from six in 2022. Consequently, the escalating demand for personalized medicine is fueling the expansion of the next-generation in vitro diagnostics (IVD) market.
What Leading Segments Are Studied In The Next-Generation In Vitro Diagnostics (IVD) Market?
The next-generation in vitro diagnostics (ivd) market covered in this report is segmented –
1) By Product Type: Consumables, Instruments, Software
2) By Diagnostic Modality: Core Laboratory Diagnostics, Point-Of-Care Testing, Molecular Diagnostics
3) By Application: Oncology Or Cancer, Infectious Diseases, Diabetes, Cardiology , Other Applications
4) By End-User: Hospitals And Clinics, Diagnostic Laboratories, Academic And Research Institutions, Other End Users
Subsegments:
1) By Consumables: Assay Kits And Reagents, Specimen Bags and Tubes, Seals and Caps
2) By Instruments: Automated Sample Preparation Systems, High-Throughput Molecular Diagnostic Analyzers, Next-Generation Sequencing Platforms, Integrated Diagnostic Workstations And Analysis Platforms, Digital PCR Systems And Advanced Real-Time PCR Instruments
3) By Software: Laboratory Information Management Systems, Specimen Tracking Software Modules, Cloud-Based Tracking Software
Which Trends Are Influencing The Development Of The Next-Generation In Vitro Diagnostics (IVD) Market?
Leading companies in the next-generation in vitro diagnostics (IVD) market are adopting an approach centered on strategic partnerships. This method in next-generation IVD involves working with technology providers, research institutions, and healthcare organizations to accelerate innovation, enhance diagnostic accuracy, and broaden access to advanced testing solutions for individuals, businesses, and governments. Strategic partnerships represent a process where companies utilize each other’s strengths and resources to achieve mutual benefits and success. For instance, in October 2024, Yourgene Health, a UK-based biotechnology company, collaborated with Genetix, a Colombia-based human genetic diagnosis company, to launch Colombia’s first local non-invasive prenatal testing (NIPT) service. This initiative signifies a notable advancement in prenatal care for the region, offering expectant parents faster, more reliable, and cost-effective access to sophisticated genetic screening. The service incorporates Yourgene Health’s IONA Nx NIPT Workflow, which is a comprehensive, CE-marked in vitro diagnostic (IVD) solution. This workflow is highly flexible and scalable, accommodating various sample volumes, and enables Genetix to provide a quality-assured prenatal screening service within Colombia.
Which Key Market Players Are Investing In Expansion And Innovation Within The Next-Generation In Vitro Diagnostics (IVD) Market?
Major companies operating in the next-generation in vitro diagnostics (ivd) market are F Hoffmann La Roche AG, Thermo Fisher Scientific Inc, Abbott Laboratories, Becton Dickinson And Company, Agilent Technologies Inc, Illumina Inc, Sysmex Corporation, Bio Rad Laboratories Inc, Revvity Inc, Exact Sciences Corporation, QIAGEN NV, DiaSorin SpA, Singular Genomics Systems Inc, Guardant Health Inc, Pacific Biosciences Of California Inc, Transasia Bio Medicals Ltd, J Mitra And Co Pvt Ltd, Roche Diagnostics International AG, Hologic Inc, Genetron Health Inc, Seegene Inc, BGI Genomics Co Ltd, Oxford Nanopore Technologies plc
Access The Complete Report For Deeper Market Insights:
Which Regions Are Projected To Dominate The Next-Generation In Vitro Diagnostics (IVD) Market In The Coming Years?
North America was the largest region in the next-generation in vitro diagnostics (IVD) market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the next-generation in vitro diagnostics (ivd) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request Your Customized Next-Generation In Vitro Diagnostics (IVD) Market Research Report for Competitive Advantage:
https://www.thebusinessresearchcompany.com/customise?id=25848&type=smp
Browse Through More Reports Similar to the Global Next-Generation In Vitro Diagnostics (IVD) Market 2026, By The Business Research Company
In Vitro Diagnostics Global Market Report 2026
https://www.thebusinessresearchcompany.com/report/in-vitro-diagnostics-global-market-report
In Vitro Diagnostic Ivd In Cardiology And Neurology Global Market Report 2026
Bioinformatics In In Vitro Diagnostics Ivd Testing Global Market Report 2026
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
